PE-22-28
Peptide Science & Research
WELL CHARACTERIZED
PROMISING
NOT YET ESTABLISHED
What Is PE-22-28?
Exploring TREK-1 Signaling, Neurobiology & Emerging Mood-Related Research
PE-22-28 is a synthetic seven-amino-acid peptide developed from research involving spadin, an endogenous peptide associated with the TREK-1 potassium channel.
Researchers developed PE-22-28 while investigating shorter spadin-derived sequences that could retain—or potentially improve—TREK-1 inhibitory activity. In laboratory testing, PE-22-28 emerged as the shortest sequence studied that maintained strong TREK-1 inhibition.
This has made PE-22-28 an intriguing research compound within the fields of neurobiology, ion-channel signaling, neuroplasticity and experimental mood-related research.
Research Status: Preclinical / Investigational.
Important: PE-22-28 is a seven-amino-acid peptide with the sequence Gly–Val–Ser–Trp–Gly–Leu–Arg. It was developed through research on spadin, a naturally occurring peptide derived from the processing of sortilin. Spadin attracted scientific attention because it blocks TREK-1 (TWIK-related potassium channel-1), a two-pore-domain potassium channel involved in regulating neuronal electrical activity. Researchers subsequently investigated shortened versions of spadin and identified PE-22-28 as a particularly potent TREK-1 inhibitor.
Why Are Researchers Interested?
PE-22-28 attracted attention because researchers weren't simply investigating another peptide associated with brain function. They were investigating a specific biological target. Research interest in this compound includes the following areas scientists have been investigating:
What The Research Suggests
PE-22-28 Is a Potent TREK-1 Blocker
The foundational 2017 study screened shortened spadin-derived peptides using human TREK-1 expressed in HEK cells.
PE-22-28 was identified as the most effective of the shortened sequences tested and was retained for additional research. Its reported IC50 was approximately 0.12 nM, compared with approximately 40–60 nM for spadin.
Why it matters: This provides PE-22-28 with a clearly defined molecular mechanism worthy of further investigation.
Animal Models Produced Antidepressant-Like Responses
Researchers subsequently evaluated PE-22-28 and related analogs using several established mouse behavioral paradigms.
The study reported antidepressant-like responses after acute and four-day subchronic administration in models including the forced-swim test, novelty-suppressed feeding and learned-helplessness testing.
These results helped establish PE-22-28 as an experimental candidate for continued research into TREK-1 and mood-related neurobiology.
Important: These are animal behavioral models. They do not establish that PE-22-28 treats depression in humans.
Shortening Spadin Didn't Eliminate Its Biological Activity
One particularly interesting aspect of the research is how PE-22-28 was discovered. Researchers studied spadin's degradation products and then designed progressively shorter sequences.
PE-22-27 and PE-22-25 did not significantly inhibit TREK-1 in the experiments, while the seven-amino-acid PE-22-28 retained substantial activity.
That allowed researchers to identify a remarkably compact sequence capable of influencing the target channel.
PE-22-28 Became a Platform for Further Peptide Design
Once PE-22-28 had been identified, researchers used it as a core peptide to develop additional analogs.
Changes to the peptide's termini and individual amino acids were tested to determine how structural modifications affected TREK-1 inhibition, stability and biological activity. Some derivatives retained strong activity, while others lost it entirely.
This makes PE-22-28 important not only as an experimental peptide itself, but also as a research framework for understanding structure–activity relationships within the TREK-1 pathway.
Evidence At A Glance
TREK-1 Potassium Channel
PE-22-28 has a clearly identified experimental target: the TREK-1 two-pore-domain potassium channel.
Potent TREK-1 Inhibition
Cell studies reported an IC50 of approximately 0.12 nM, substantially lower than that reported for parent peptide spadin.
Mood-Related Animal Models
Antidepressant-like behavioral effects have been reported in mouse research using several established experimental paradigms.
Neuroplasticity & Peptide Optimization
PE-22-28 has become a foundation for designing and investigating additional TREK-1-targeting peptide analogs.
Preclinical Evidence
The evidence identified for PE-22-28 is based on laboratory and animal research rather than controlled human clinical trials.
Safety & Limitations
PE-22-28 remains an early-stage investigational peptide. The published research provides intriguing mechanistic and preclinical findings, but those findings should be interpreted within their proper scientific context.
Current limitations include: Published evidence is predominantly preclinical. Human therapeutic effectiveness has not been established. Human dosing has not been established. Long-term human safety has not been established. Results from mouse behavioral models cannot automatically be translated into human psychiatric outcomes. Potent activity against a molecular target does not by itself establish clinical benefit.
The 2017 researchers also evaluated activity against the hERG potassium channel, an important cardiac safety screening target, and reported that PE-22-28 and the tested analogs did not modify hERG activity under the experimental conditions studied. That is an encouraging preclinical safety observation, but it is not equivalent to establishing safety in humans.
Regulatory Status
PE-22-28 is not an FDA-approved medication. It has not received FDA approval for depression, anxiety, cognitive enhancement, neuroplasticity or another therapeutic indication.
The research identified for this review remains preclinical, and the published literature should therefore be understood as experimental neuroscience research rather than evidence of an established therapy.
No Established Human Indication
The published evidence reviewed here does not establish: Approved human indications • standardized clinical dosing • established human efficacy • established long-term human safety.
This is an important distinction because the scientific interest surrounding PE-22-28 is based primarily on its mechanism and preclinical findings.
Regulatory Status — PE-22-28: Not FDA-approved. PE-22-28 has not received FDA approval for any therapeutic indication. The published research remains preclinical and should be understood as experimental neuroscience research rather than evidence of an established therapy. No approved human indications, standardized clinical dosing, established human efficacy, or established long-term human safety have been established.
PE-22-28 vs. Spadin
Same Research Pathway — Different Peptides. Spadin and PE-22-28 are related, but they are distinct peptides.
Spadin
Parent research peptide — Spadin is an endogenous peptide associated with sortilin processing and was identified as a selective blocker of TREK-1. Research focus: TREK-1 signaling • antidepressant-related animal models • neurogenesis • neuroplasticity.
PE-22-28
Optimized shortened sequence — PE-22-28 is a seven-amino-acid sequence developed through investigation of shortened spadin-derived peptides. Research focus: TREK-1 inhibition • peptide optimization • stability • mood-related animal models • neuroscience.
THE KEY DISTINCTION: Research involving spadin provides important scientific context for understanding why PE-22-28 was developed and why TREK-1 is being investigated. However, they are distinct peptides. Evidence involving spadin should not automatically be presented as direct evidence for PE-22-28.
Research & Publications
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
Djillani A, Pietri M, Moreno S, et al. — Frontiers in Pharmacology, 2017
The key PE-22-28 publication. Researchers developed shortened spadin analogs and identified PE-22-28 as a potent TREK-1 inhibitor. The study included cellular electrophysiology, stability experiments and mouse behavioral models.
View on PubMedFighting Against Depression With TREK-1 Blockers: Past and Future — A Focus on Spadin
Pharmacology & Therapeutics, 2019
A scientific review examining the development of TREK-1 blockers, including the progression from spadin toward shortened analogs such as PE-22-28. The review discusses PE-22-28's potency, selectivity, animal research and the continuing development of TREK-1-targeted peptides.
View ArticlePE-22-28: Research Is Still Developing.
PE-22-28 represents an interesting example of targeted peptide engineering. Rather than being discovered simply because a naturally occurring peptide showed an interesting effect, PE-22-28 emerged through a systematic process: Identify a neurological target → study its endogenous peptide regulator → examine peptide degradation → shorten the sequence → measure channel activity → evaluate stability → investigate biological effects.
That progression makes PE-22-28 scientifically interesting. The published evidence suggests that this very small seven-amino-acid peptide can potently and selectively influence TREK-1 activity under experimental conditions, while animal studies provide an early foundation for investigating how that mechanism could affect mood-related neurobiology.
At the same time, PE-22-28 remains firmly within the preclinical research stage. More research—including controlled human studies—would be necessary to determine whether these experimental findings translate into safe or effective clinical applications.
Educational information only — not medical advice.